Chaque semaine, la rédaction du JDNews vous partage ses bonnes nouvelles. Au menu : Jean-Pascal Zadi en tête d’affiche des ...

Le laboratoire israélien Teva, géant des médicaments génériques, a annoncé mercredi avoir de nouveau subi de lourdes pertes en 2024, notamment parce que la vente programmée de ...

La Bourse de New York a terminé dans le rouge vendredi, lestée par quelques prises de bénéfices après une semaine agitée par ...

La Bourse de New York a ouvert sans grande conviction vendredi, les investisseurs assimilant une première série d’annonces de ...

Selon l’agence nationale de sécurité du médicament (ANSM), environ 700 000 personnes en France prennent des analogues du ...

Semaglutide is now approved for reducing the risk for worsening kidney disease and cardiovascular death in adults with ...

One in eight adults in the U.S. has taken Ozempic or another type of GLP-1 drug, surveys show — and now a major new study has revealed a long list of benefits and some little-known risks.

The drug Ozempic is not registered for sale in Trinidad and Tobago, says secretary/treasurer of the Pharmacy Board of Trinidad and Tobago, Sanjay Mohammed. He made the disclosure during a Joint ...

A major analysis of more than 1.2 million medical records has found popular diabetes and weight loss drugs, including Ozempic and Wegovy, may also reduce the risk of other health issues.

Few drugs have captured public attention like Ozempic; many of us have even taken it. The type 2 diabetes medication, generically known as semaglutide, has received unprecedented attention in the ...

Most people know that GLP-1 receptor agonist medications like Ozempic and Wegovy can cause relatively minor side effects like nausea and diarrhea. But new research confirms that more serious ...